Download Files:
BGT226
$120 – $990
Products Details
Product Description
– BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].
Web ID
– HY-13334A
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H25F3N6O2
Citations
– Molecules. 2020 Apr 23;25(8):1980.|Front Pharmacol. 2020 Nov 11;11:580407.|Harvard Medical School LINCS LIBRARY|Research Square Print. 2023 Mar 9.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
References
– [1]Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012 Sep;23(9):2399-408.|[2]Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011 Nov 15;17(22):7116-26.
CAS Number
– 915020-55-2
Molecular Weight
– 534.53
Compound Purity
– 99.51
SMILES
– O=C(N1C2=CC=C(N3CCNCC3)C(C(F)(F)F)=C2)N(C)C4=C1C5=CC(C6=CC=C(OC)N=C6)=CC=C5N=C4
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Autophagy;mTOR;PI3K
Isoform
– mTOR;PI3Kα;PI3Kβ;PI3Kγ
Pathway
– Autophagy;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
